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AbstrAct
ObjeCtive
To compare the effectiveness and acceptability of 
outpatient polypectomy with inpatient polypectomy.
Design
Pragmatic multicentre randomised controlled non-
inferiority study.
setting
Outpatient hysteroscopy clinics in 31 UK National 
Health Service hospitals.
PartiCiPants
507 women who attended as outpatients for diagnostic 
hysteroscopy because of abnormal uterine bleeding 
and were found to have uterine polyps.
interventiOns
Participants were randomly assigned to either outpatient 
uterine polypectomy under local anaesthetic or inpatient 
uterine polypectomy under general anaesthesia. Data 
were collected on women’s self reported bleeding 
symptoms at baseline and at 6, 12, and 24 months. Data 
were also collected on pain and acceptability of the 
procedure at the time of polypectomy.
Main OutCOMe Measures
The primary outcome was successful treatment, 
determined by the women’s assessment of bleeding at 
six months, with a prespecified non-inferiority margin 
of 25%. Secondary outcomes included generic (EQ-5D) 
and disease specific (menorrhagia multi-attribute 
scale) quality of life, and feasibility and acceptability 
of the procedure.
results
73% (166/228) of women in the outpatient group and 
80% (168/211) in the inpatient group reported successful 
treatment at six months (intention to treat relative risk 
0.91, 95% confidence interval 0.82 to 1.02; per protocol 
relative risk 0.92, 0.82 to 1.02). Failure to remove polyps 
was higher (19% v 7%; relative risk 2.5, 1.5 to 4.1) and 
acceptability of the procedure was lower (83% v 92%; 
0.90, 0.84 to 0.97) in the outpatient group Quality of life 
did not differ significantly between the groups. Four 
uterine perforations, one of which necessitated bowel 
resection, all occurred in the inpatient group.
COnClusiOns
Outpatient polypectomy was non-inferior to inpatient 
polypectomy. Failure to remove a uterine polyp was, 
however, more likely with outpatient polypectomy and 
acceptability of the procedure was slightly lower.
trial registratiOn
International Clinical Trials Registry 65868569.
Introduction
Abnormal uterine bleeding affects women of all ages 
and is the commonest gynaecological reason for referral 
to secondary care.1 2 Uterine polyps are focal outgrowths 
of the endometrium and are often found in association 
with uterine bleeding in both premenopausal and post-
menopausal women.3 4 Such polyps are detected in an 
estimated 20–40% of women with abnormal uterine 
bleeding3–7 following outpatient investigation with 
 pelvic ultrasonography or hysteroscopy. The available 
evidence supports the current practice of surgically 
removing uterine polyps to help alleviate the symptoms 
of bleeding.8 9 Conventional practice is to undertake this 
procedure under general anaesthesia in hospital. How-
ever, with advances in endoscopic technology it is now 
possible to perform uterine polypectomy under hystero-
scopic guidance in an outpatient setting without the 
need for hospital admission and anaesthesia.10–12 Fur-
thermore, treatment can be carried out at the same time 
as diagnosis; the “see and treat” approach.13
The convenience and immediacy of outpatient treat-
ment may seem advantageous over traditional practice. 
However, the limitations of operating in the genital 
tract using miniature equipment in a conscious patient 
may offset any apparent benefits. We carried out a mul-
ticentre, pragmatic, non-inferiority, randomised con-
trolled trial (the Outpatient Polyp Treatment trial) to 
evaluate the effectiveness and acceptability of outpa-
tient polyp treatment compared with traditional inpa-
tient surgical treatment.
Methods
Population
All women with abnormal uterine bleeding and a uter-
ine polyp diagnosed at outpatient hysteroscopy13 were 
eligible to be recruited into the trial. Abnormal uterine 
WhAt Is AlreAdy knoWn on thIs topIc
A systematic review identified just two small comparative studies that evaluated 
outpatient versus inpatient polypectomy and found no difference in improvement 
of symptoms
The available data do not provide precise estimates of relative effectiveness, and 
the rates of technical failure, patient acceptability, and cost effectiveness are 
uncertain
WhAt thIs study Adds
In this study outpatient polypectomy was not inferior to inpatient polypectomy for 
the relief of abnormal bleeding associated with uterine polyps, confirming the 
provisional findings from earlier small, comparative studies
The overall safety, feasibility, and acceptability of outpatient polypectomy support 
the implementation of outpatient hysteroscopic services
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bleeding included heavy menstrual bleeding, intermen-
strual bleeding, and postmenopausal bleeding. Women 
were excluded before randomisation if outpatient pol-
ypectomy was considered not feasible, malignancy was 
suspected, or another surgical uterine intervention was 
needed. All participants provided written informed 
consent. In clinics that provided a “see and treat” ser-
vice, consent was obtained and the patient was regis-
tered on the online randomisation system before the 
diagnostic hysteroscopy, so that if a uterine polyp was 
diagnosed, randomisation could be performed quickly, 
without a lengthy interruption, should outpatient pol-
ypectomy be allocated.
randomisation and blinding
Patients were randomised in a 1:1 ratio to removal of 
uterine polyps in either an outpatient or an inpatient 
setting using a web based central randomisation ser-
vice at the University of Birmingham Clinical Trials 
Unit. Blinding of the patients and clinicians was not 
possible owing to the nature of the interventions. Mini-
misation was used to achieve balance between groups 
for predominant bleeding (heavy, intermenstrual, or 
postmenopausal), location (fundal or non-fundal), and 
type of polyp (glandulocystic or fibrous).
Procedures
After the diagnostic hysteroscopy, we randomised eligi-
ble women. Those allocated outpatient polypectomy in 
most instances underwent the procedure immediately 
after diagnosis, although some participants had their 
treatment scheduled, depending on local circum-
stances, within the next eight weeks. Outpatient polyp-
ectomies were performed in the outpatient hysteroscopy 
clinic and inpatient procedures were performed in oper-
ating theatres, under general or regional anaesthesia. 
Polyp removal was carried out under direct hystero-
scopic vision using miniature mechanical or electrosur-
gical instruments, with or without the need for minor 
degrees of cervical dilatation and local anaesthesia 
(direct cervical infiltration or paracervical injection). 
Blind avulsion with small polypectomy forceps was also 
allowed. In addition, women allocated inpatient polyp-
ectomy could have traditional dilatation and curettage 
or polyp removal under vision using a resectoscope. 
Clinicians were free to choose the technique for polyp-
ectomy post-randomisation. Endometrial biopsy and 
medical treatments were permitted when indicated.
Outcome measures and follow-up
The primary outcome was successful treatment, deter-
mined by the women’s assessment of their bleeding at 
six months using a dichotomous (success or fail) out-
come measure. For women with heavy menstrual bleed-
ing, we considered treatment to be a success if bleeding 
had reduced to acceptable levels. For women with inter-
menstrual or postmenopausal bleeding the definition 
was cessation of bleeding. We considered this outcome 
to be the most clinically relevant and it was assessed 
using a non-inferiority framework with a prespecified 
margin of 25%.
Secondary measures of bleeding outcome included 
women’s subjective assessment of their bleeding using 
visual analogue scales (0 for no bleeding to 100 heavi-
est imaginable and 0 for no days bleeding to 100 for 
bleeding every day) and response to the question 
“compared to before your treatment, would you say 
your bleeding is?” on an ordered Likert scale (much 
better, little better, same, worse). We measured health 
related quality of life using the generic EuroQol 
EQ-5D-3L14 and the disease specific menorrhagia 
multi-attribute scale.15 All clinical data were collected 
at baseline and then by post at 6, 12, and 24 months 
post-randomisation.
We also evaluated patient experience by asking the 
women to rate their level of pain one hour after the pro-
cedure and on discharge from hospital using a visual 
analogue scale (0 no pain to 100 worst imaginable 
pain). Women undergoing outpatient polypectomy also 
rated the level of pain during the procedure. Acceptabil-
ity of the procedure was assessed using Likert scales 
and structured questions. This was supplemented by a 
series of semistructured qualitative telephone inter-
views in a purposive sample of women one week after 
the procedure. We collected perioperative and postop-
erative data and included rates of successful polyp 
removal, complications, adverse events, and further 
treatment.
study oversight
An independent trial steering committee and an inde-
pendent data monitoring and ethics committee pro-
vided oversight for the study; on the basis of three 
reviews of interim data there was no reason to stop or 
modify the trial on the basis of pragmatic stopping 
criteria.16
statistical analysis
The sample size was based on data suggesting that 
patient rated success of treatment at six months would 
be 90% for inpatient polypectomy and 80% for outpa-
tient polypectomy.12 We determined that to show with 
90% power (two sided P<0.05) that success rates with 
outpatient polypectomy were no lower than 68% (a 25% 
non-inferiority margin) required 400 women. This was 
increased to 480 to allow for 15% loss to follow-up. The 
prespecified non-inferiority margin of 25% (relative 
reduction) was based on the assumptions that outpa-
tient polypectomy would be more convenient for 
women and cheaper, permitting it to be considered the 
treatment of choice even if fewer women had alleviation 
of bleeding symptoms.
Primary analyses were by intention to treat, but we 
also carried out per protocol sensitivity analyses for the 
primary outcome as protection against any theoretical 
increase in the risk of type I error.17 The per protocol 
analysis included only those women who received their 
allocated treatment. For the primary outcome we calcu-
lated point estimates and two sided 95% confidence 
intervals from unadjusted risk ratios; the study could 
only declare non-inferiority if the lower band of the con-
fidence interval was not lower than 0.75. We performed 
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extensive sensitivity analysis on the primary outcome, 
particularly for missing responses.
Using analysis of covariance we analysed secondary 
endpoints measured on continuous scales at each time 
point, adjusting for baseline score, along with a further 
repeated measures analysis including all assessment 
time points.18 Models here included variables allowing 
for group, time, and baseline score. To test for differ-
ences in efficacy between prespecified subgroups for 
the primary outcome, we included treatment by sub-
group interaction variables in the linear model. We 
calculated adjusted estimates of difference for the pri-
mary and main patient reported secondary outcomes 
through the addition of the minimisation variables to 
the corresponding linear models. Output here was sim-
ilar to the unadjusted results. We used paired t tests to 
analyse changes from baseline score within groups. 
Standard tests were used for other outcome measures: 
Cochran-Armitage test for trend for ordinal responses, 
t  tests for continuous data, and χ2 tests for binary 
responses. The non-inferiority hypothesis did not apply 
for these other end points; we present 95% confidence 
intervals and P values from two sided superiority tests. 
SAS version 9.2 was used for analyses.
results
Patients and follow-up
Overall, 507 women with abnormal uterine bleeding 
and uterine polyps from 31 UK National Health Service 
centres were randomised between April 2008 and July 
2011. Baseline characteristics of the women in both 
groups were similar (table 1). For 45% (227/507) of those 
randomised, the initial problem was postmenopausal 
bleeding, 30% (153/507) had heavy menstrual bleeding, 
and 25% (127/507) had intermenstrual bleeding. In 
total, 230/254 (91%) women in the outpatient group 
received their randomised allocation compared with 
206/253 (81%) in the inpatient group (fig 1). Seventy two 
per cent (174/242, 12 dates missing) of the women allo-
cated to outpatient polypectomy were treated in see and 
treat clinics. Primary outcome responses were available 
from 439/507 (87%) participants at six months. Twenty 
eight women underwent qualitative telephone inter-
views.
Primary outcome: treatment success
Overall, 73% (166/228) of women in the outpatient poly-
pectomy group and 80% (168/211) in the inpatient poly-
pectomy group reported a successful response to 
surgery at six months (intention to treat relative risk 
0.91, 95% confidence interval 0.82 to 1.02; per protocol 
relative risk 0.92, 95% confidence interval 0.82 to 1.02). 
The lower ends of the confidence intervals showed that 
outpatient polypectomy was at most 18% worse than 
inpatient treatment and was within the 25% margin of 
non-inferiority (fig 2). In absolute terms this translated 
to a number needed to treat to harm of 15 with outpa-
tient treatment (95% confidence interval number 
needed to treat to harm of 6 to number needed to benefit 
of 39). By one and two years the corresponding propor-
tions were similar between groups, producing relative 
risks close to unity (see supplementary table A1). Treat-
ment effect did not seem to differ according to any of the 
predefined subgroups; predominant bleeding com-
plaint, polyp site and type, or through the various sen-
sitivity analyses performed (see supplementary tables 
A2-A4).
Operative results
Partial or failed removals occurred in 46/242 (19%) of 
the outpatient group and 18/233 (7%) in the inpatient 
group (relative risk 2.5, 95%confidence interval 1.5 to 
4.1; P<0.001). The most common reason for incomplete 
removal in the outpatient group was patient discomfort 
(table 2). Overall, 25/46 (54%) of the failed outpatient 
removals were immediately scheduled for reoperation, 
usually as an inpatient (23/25, 92%). Over the two year 
follow-up period, 43 women in the outpatient group 
and 21 in the inpatient group had a further polyp 
removal (2.0, 1.2 to 3.3, P=0.003, fig 1).
serious adverse events
Four uterine perforations (4/233, 2%) occurred in the 
inpatient group. One of these involved a bowel injury, 
requiring laparotomy and a small bowel resection. One 
woman needed an indwelling catheter after inpatient 
table 1 | baseline characteristics of women receiving polypectomy for abnormal uterine 
bleeding. values are numbers (percentages) unless stated otherwise
Characteristics
Outpatient 
polypectomy (n=254)
inpatient 
polypectomy (n=253)
Mean (SD) age (years) 50 (10) 51 (11)
Ethnicity:
 White 207 (88) 179 (87)
 Asian 17 (7) 16 (7)
 Black 11 (5) 9 (4)
 Other 1 (<1) 1 (<1)
 Not given/not known 18 48
Predominant bleeding complaint at randomisation*:
 Postmenopausal† 113 (44) 114 (45)
 Heavy menstrual‡ 77 (30) 76 (30)
 Intermenstrual§ 64 (25) 63 (25)
Site of uterine polyp*:
 Fundal 99 (39) 99 (39)
 Non-fundal 155 (61) 154 (61)
Type of uterine polyp*:
 Glandular 190 (75) 188 (74)
 Fibrous 64 (25) 65 (26)
No of polyps:
 1 193 (76) 201 (79)
 2 40 (16) 43 (17)
 ≥3 21 (8) 9 (4)
Other benign disease:
 None 251 (99) 250 (99)
 Submucosal fibroid, adhesion, and septum 0 1 (<1)
 Adhesion and septum 0 1 (<1)
 Submucosal fibroid 2 (1) 0
 Septum 1 (<1) 1 (<1)
10 women (2%) had a history of taking tamoxifen (five allocated to each group). Five of these were currently 
taking the treatment (two in inpatient group, three in outpatient group).
*Minimisation variable and predefined subgroup.
†29 of these women (13%) were currently taking a continuous combined “no bleed” hormone replacement 
therapy (14 allocated inpatient, 15 allocated outpatient).
‡Includes one postmenopausal woman (1%) taking sequential hormone replacement therapy (allocated 
inpatient).
§Includes six postmenopausal women (5%) taking a sequential hormone replacement therapy (two allocated 
inpatient, four allocated outpatient).
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polypectomy and one woman was admitted to a high 
dependency unit for the period of her outpatient proce-
dure as she had recently experienced a myocardial 
infarction. No serious adverse events occurred in the 
outpatient group.
Quality of life and bleeding scores
Condition specific and generic quality of life scores 
were significantly improved from baseline at all time 
points in both groups, with no differences between 
them (table 3) (see also supplementary table A5).
Procedure acceptability
Mean pain scores were higher in the outpatient group 
than in the inpatient group (table 3). Treatment was 
unacceptable for 2% of women in each group (5/225 
inpatient; 3/197 outpatient, relative risk 0.7, 95% 
 confidence interval 0.2 to 2.8; P=0.6), but women in the 
outpatient group were less likely to recommend the 
procedure to a friend or to have it again if necessary 
(see also supplementary table A6). In qualitative inter-
views, women in the outpatient group balanced pain, 
which they mainly experienced short term, with the 
convenience of a fast response to their problem.
additional treatments
The groups did not differ for the number of women 
using additional medical treatments for their bleeding 
or consulting a healthcare provider during the two 
years of follow-up. An increased number of women in 
the outpatient group underwent further gynaecologi-
cal surgery (excluding polypectomy); 61/230 (27%) v 
36/219 (16%), relative risk 1.6 (95% confidence interval 
1.1 to 2.3); P=0.01), see supplementary tables A7–10). 
Overall, 7/449 (1.6%, 95% confidence interval 0.6% to 
3.2%) women developed endometrial cancer during 
the two years of follow-up, of whom four had been 
treated in the outpatient setting and three in the inpa-
tient setting.
discussion
The results of this trial show that outpatient polypec-
tomy is non-inferior to inpatient polypectomy for the 
successful alleviation of uterine bleeding associated 
with uterine polyps. At six months 73% (166/228) of 
women who received outpatient treatment and 80% 
(168/211) who received inpatient treatment were suc-
cessfully treated, and the treatment effects were main-
tained at 12 and 24 months. There was no evidence that 
successful resolution of symptoms varied by primary 
bleeding complaint, or polyp type and location. The 
duration and amount of bleeding were significantly 
reduced after both outpatient and inpatient treatment, 
with no difference between the groups. Similarly, a 
non-differential but significant improvement in generic 
and disease specific quality of life was seen after polyp-
ectomy. Over the two year follow-up period, women 
treated in the outpatient setting were twice as likely to 
Intention to treat
  Six months
  One year
  Two years
Per protocol
  Six months
  One year
  Two years
0.5 0.7 1
Relative risk (95% CI)Favours inpatient polypectomy
Margin of non-inferiority (0.75)
Fig 2 | Primary outcome (successful treatment, determined 
by the women’s assessment of their bleeding at six 
months) compared with margin of non-inferiority
Inpatient polypectomy (n=253):
Received randomised allocation (general or
  regional anaesthetic) (n=206; 81%)
Received outpatient polypectomy (local or no
  anaesthetic) (n=34; 13%)
Did not have operation (n=13; 5%)
Outpatient polypectomy (n=254):
Received randomised allocation (local or no
  anaesthetic) (n=230; 91%)
Received inpatient polypectomy (general
  anaesthetic) (n=14; 6%)
Did not have operation (n=10; 4%)
Available for analysis of primary outcome at six
  months (n=228)
Reoperations (n=31; 14%):
  Inpatient (n=24)
  Outpatient (n=6)
  Unknown (n=1)
Available for analysis of primary
outcome at one year (n=225)
Available for analysis of primary
outcome at one year (n=214)
Available for analysis of primary outcome at six
  months (n=211)
Reoperations (n=6; 3%):
  Inpatient (n=3)
  Outpatient (n=3)
Available for analysis of primary outcome at
  two years (n=213)
Reoperations (n=12; 6%)
  Inpatient (n=2)
  Outpatient (n=9)
  Unknown (n=1)
Available for analysis of primary outcome at
  two years (n=196)
Reoperations (n=8; 4%)
  Inpatient (n=3)
  Outpatient (n=3)
  Unknown (n=2)
Randomised and assessed for eligibility by hysteroscopy (n=1537)
Randomised (n=507)
Not randomised (n=1030):
  No benign polyps (n= 800)
  Polypectomy not required (n=72)
  Hysteroscopy not feasible (n=58)
  Not feasible to remove polyps in an outpatient setting (n=40)
  Possible malignant lesion (n=22)
  Need for other uterine surgical intervention (n=15)
  Consent withdrawn (n=4)
  Patient missed appointment (n=2)
  Hysterectomy required (n=1)
  Non-surgical treatment required (n=1)
  No abnormal uterine bleeding (n=1)
  Missing information (n=14)
Exited trial (n=39):
  Lost to follow-up (n=29)
  Contacted and did not wish to complete
    any more follow-up forms (n=10)
(3 also missed six month time-point but
  available at one year)
Exited trial (n=18):
  Died (n=3)
  Lost to follow-up (n=8)
  Contacted and did not wish to complete
    any more follow-up forms (n=7)
Exited trial (n=26):
  Lost to follow-up (n=24)
  Contacted and did not wish to complete
    any more follow-up forms (n=2)
Exited trial (n=3):
  Died (n=1)
  Contacted and did not wish to complete
    any more questionnaires (n=2)
Exited trial (n=12):
  Lost to follow-up (n=9)
  Contacted and did not wish to complete
    any more follow-up forms (n=3)
Fig 1 | Flow chart showing enrolment, randomisation, and follow-up of participants. 
a small number of women had more than one reoperation
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table 2 | Operative and postoperative details. values are numbers (percentages) of women unless stated otherwise
Operative/postoperative variable Outpatient polypectomy inpatient polypectomy
Mean difference or relative 
risk (95% Ci), P value*
Median (interquartile range) largest polyp size (cm), No 1.0 (0.6–2.0), 230 1.2 (1.0–2.0), 217 −0.2 (−0.3 to 0.0), 0.04
Required cervical dilation (No/No in group (%)) 76/241 (32) 178/232 (77) 0.41 (0.34 to 0.50), <0.001
Use of vaginal speculum (No/No in group (%)) 126/236 (53) 193/224 (86) 0.62 (0.54 to 0.71), <0.001
Use of local anaesthetic (No/No in group (%)) 91/244 (37) 15/240 (6) 6.0 (3.6 to 10.0), <0.001
Removal by hysteroscopy† (No/No in group (%)) 175/225 (78) 122/217 (56) 1.4 (1.2 to 1.6), <0.001
Median (interquartile range) hysteroscope diameter (mm), No 4.0 (3.0–4.0), 148 5.0 (5.0–6.0), 136 −1.5 (−2.0 to −1.0), <0.001
Method for detachment: n=228 n=222 1.6 (1.3 to 2.0)‡, <0.001
 Electrode 124 (54) 75 (34)
 Mechanical 89 (39) 139 (63)
 Combination 15 (7) 8 (4)
Method of retrieval: n=227 n=223 2.2 (1.7 to 2.9)§, <0.001
 None 37 (16) 15 (7)
 Hysteroscopic 127 (56) 56 (25)
 Mechanical 59 (26) 147 (66)
 Combination 4 (2) 5 (2)
Surgeon grade: consultant¶ (No/No in group (%)) 172/244 (70) 153/236 (65) 1.1 (1.0 to 1.2), 0.2
Median (interquartile range) time between randomisation  
and treatment (days), No
0 (0–14), 242 26 (14–42), 237 −20 (−22 to −18), <0.001
Mean (SD) time taken for polypectomy (mins), No 11 (8), 223 12 (8), 186 −1 (−3, 0 to 0.07)
Mean (SD) time in outpatient room/theatre (mins), No 29 (15), 225 29 (13), 216 −1 (−3.2 to 0.7)
Success of removal: n=242 n=233 2.5 (1.5 to 4.1),** <0.001
 Complete 196 (81) 215 (92)
 Partial 25 (10) 15 (6)
 Failed 21 (9) 3 (1)
Planned reoperation 25 (10)†† 1 (<1)††
Reasons for partial/failed removal: n=242 n=233
 Patient discomfort 22 (9) 1 (<1)
 Unable to locate blindly 7 (3) 5 (2)
 Unable to access under vision 4 (2) 2 (1)
 Inadequate visualisation 3 (1) 2 (1)
 Polyp/fibroid too large 6 (2) 0
 Uterine perforation 0 2 (1)
 Equipment failure 1 (<1) 0
 Missing reason 1 (<1) 0
 Other‡‡ 2 (1) 6 (3)
Operative complications: n=241 n=233
 Vasovagal episode 17 (7) 3 (1)
 Nausea/pain 4 (2) 0
 Cervical trauma 0 3 (1)
 Uterine perforation 0 4 (2)
 Haemorrhage 0 3 (1)
 Other§§ 2 (1) 1 (<1)
Postoperative complications: n=232 n=223
 Vasovagal episode 15 (6) 3 (1)
 Vomiting 6 (3) 4 (2)
 Dizziness/nausea 5 (2) 2 (1)
 Severe pain 3 (1) 0
 Other¶¶ 2 (1) 2 (1)
Further treatment/procedure given: n=229 n=222
 Levonorgestrel intrauterine system 31 (14) 43 (19)
 Tranexamic acid 12 (5) 1 (<1)
 Progestins 8 (3) 0
 Endometrial destruction 4 (2) 1 (<1)
 Mefenamic acid 1 (<1) 1 (<1)
 Hysterectomy 1 (<1) 1 (<1)
 Goserelin acetate 2 (1) 0
 Missing reason 0 1 (<1)
 Other*** 0 1 (<1)
*P values from two sided tests for superiority where given. Mean differences and relative risks <0 indicate lower with outpatient polypectomy. For skewed variables presented with medians, 
differences in location between groups were calculated using Hodges-Lehmann estimates and Moses’ confidence intervals. Complication rates and reason for failure were not formally 
analysed.
†Versus blind removal.
‡Relative risk calculated from electrode versus any other category.
§Relative risk calculated from hysteroscopic versus any other category.
¶Versus staff grades less than consultant.
**Relative risk calculated from partial or failed versus complete.
††23/25 (92%) planned reoperations in outpatient group were to be as inpatient. The single planned reoperation in the inpatient group was to be as a further inpatient.
‡‡Outpatient polypectomy: polyp biopsied and ablated (n=1), difficult procedure (n=1); inpatient polypectomy: actually a fibroid (n=2), broad stem (n=1), removal by forceps (n=1), difficult 
procedure (n=1), failure by diathermy (n=1).
§§Outpatient polypectomy: perineal numbness (n=1), diclofenac suppository given postoperatively (n=1); inpatient polypectomy: false passage (n=1).
¶¶Outpatient polypectomy: not given (n=1), complication from entonox (n=1); inpatient polypectomy: antibiotics required owing to uterine perforation (n=1), intravenous cannula site pain (n=1).
***Transcervical resection of fibroids.
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table 3 | results of quality of life assessments, bleeding, pain scores, and acceptability of procedure. values are means (standard deviations), (number) 
unless stated otherwise
variables
Mean (sD), no
Mean difference or relative 
risk (95% Ci), P value*
Outpatient 
polypectomy
inpatient 
polypectomy
Quality of life and bleeding scores
Menorrhagia multi-attribute scale†:
 Baseline 52 (27), 134 58 (24), 124
 Six months 78 (22), 115‡ 79 (23), 99‡ −1 (−7 to 5), 0.68
 One year 82 (23), 110‡ 83 (21), 101‡ −1 (−7 to 5), 0.78
 Two years 84 (21), 93‡ 85 (21), 83‡ −2 (−8 to 4), 0.47
 Overall§ −1 (−6 to 4), 0.65
EuroQol EQ-5D¶:
 Baseline 0.78 (0.25), 242 0.78 (0.27), 232
 Six months 0.87 (0.23), 230‡ 0.87 (0.20), 211‡ −0.01 (−0.04 to 0.03), 0.70
 One year 0.86 (0.25), 227‡ 0.86 (0.24), 219‡ 0.00 (−0.04 to 0.04), 0.85
 Two years 0.85 (0.25), 213‡ 0.84 (0.27), 196 0.03 (−0.02 to 0.07), 0.28
 Overall§ 0.00 (−0.03 to 0.03), >0.99
EuroQol health thermometer**:
 Baseline 77 (18), 233 78 (18), 225
 Six months 79 (18), 227‡ 80 (17), 212 0 (−3 to 3), 0.89
 One year 80 (17), 228‡ 82 (16), 219‡ −1 (−4 to 2), 0.50
 Two years 79 (18), 207 83 (16), 194‡ −2 (−5 to 1), 0.19
 Overall§ −1 (−3 to 1), 0.28
Bleeding duration visual analogue scale††:
 Baseline 46 (28), 68 53 (28), 67
 Six months 35 (30), 64 28 (26), 56‡ −10 (−21 to 1), 0.07
 One year 18 (21), 58‡ 24 (28), 62‡ 5 (−5 to 14), 0.32
 Two years 16 (22), 61‡ 15 (25), 53‡ −2 (−12 to 8), 0.65
 Overall§ −3 (−10 to 4), 0.39
Bleeding amount visual analogue scale‡‡:
 Baseline 58 (28), 70 66 (26), 68
 Six months 29 (29), 68‡ 29 (29), 58‡ −1 (−12 to 9), 0.82
 One year 23 (26), 66‡ 19 (22), 66‡ −4 (−12 to 5), 0.36
 Two years 19 (24), 63‡ 18 (27), 57‡ −2 (−12 to 8), 0.66
 Overall§ −3 (−10 to 4), 0.40
Operation pain scores:
 During procedure§§ 45 (26), (217) Not applicable Not applicable
 60 minutes after procedure§§ 28 (23), (176) 23 (22), (191) −5 (−10 to 0), 0.03
 On discharge§§ 23 (21), (200) 15 (17), (186) −8 (−12 to −4), <0.001
Operation acceptability
Procedure acceptable (No, %):
 Totally 136 (60) 152 (77)
 Generally 51 (23) 30 (15) 0.90 (0.84 to 0.97), <0.001¶¶
 Fairly 33 (15) 12 (6)
 Unacceptable 5 (2) 3 (2)
Exposure embarrassing (No, %):
 Extremely 5 (2) 4 (2)
 Moderately 17 (8) 24 (12) 1.45 (0.86 to 2.46), 0.24***
 A little 79 (35) 35 (18)
 No 123 (55) 133 (68)
Would recommend to a friend, No/No in group (%) 205/222 (92) 190/196 (97) 0.95 (0.91 to 1.00), 0.04
Would have same treatment again, No/No in group (%) 200/223 (90) 186/193 (96) 0.93 (0.88 to 0.98), 0.009
Prefer alternative treatment, No/No in group (%) 47/218 (22) 39/190 (21) 0.95 (0.65 to 1.39), 0.80
*P values from two sided tests for superiority. Estimates of differences >0 favour outpatient polypectomy, <0 favour inpatient polypectomy (for continuous responses), similarly estimates of 
relative risk >1 favour outpatient polypectomy, <1 favour inpatient polypectomy (for dichotomous responses). When baseline scores were available, difference between groups at each time 
point was adjusted for baseline score.
†Menorrhagia multi-attribute scale questionnaire: scores range from 0 (severely affected) to 100 (not affected); restricted to those with heavy menstrual and intermenstrual bleeding only.  
and time (see statistical analysis section for details).
‡P<0.05 when compared with baseline score within group (by paired t test).
§Overall estimate is mean difference over all time points using a repeated measures model including variables adjusting for group, baseline score and time (see statistical analysis section for 
details).
¶Health related quality of life questionnaire: scores range from −0.59 (health state worse than death) to 1.0 (perfect health state).
**Health related quality of life questionnaire: scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).
††Visual analogue scale score: scores range from 0 (no days of bleeding in past month) to 100 (bleeding every day in past month); restricted to those with heavy menstrual bleeding only.
‡‡Visual analogue scale score: scores range from 0 (no bleeding in past month) to 100 (heaviest imaginable bleeding in past month); restricted to those with heavy menstrual bleeding only.
§§Visual analogue scale score; scores range from 0 (no pain at all) to 100 (worst imaginable pain). t test used for analysis.
¶¶Cochran-Armitage test for trend used for analysis; totally acceptable/generally acceptable versus fairly acceptable/unacceptable combined categories used to calculate relative risk.
***Cochran-Armitage test for trend used for analysis; extremely/moderately versus a little/no combined categories used to calculate relative risk.
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undergo at least one further polyp removal and 1.6 
times more likely to have further gynaecological sur-
gery. These observations may imply reduced effective-
ness of outpatient compared with inpatient 
polypectomy. However, the increased rates of further 
gynaecological surgery in women undergoing treat-
ment as an outpatient could be because they were more 
willing to seek referral and treatment for ongoing or 
new gynaecological problems because of the perceived 
convenience of their initial experience.
Despite fewer serious complications and avoiding 
hospital admission and general anaesthesia, the out-
patient procedure was associated with more technical 
failures, increased postoperative pain, and reduced 
acceptability to patients. Over 90% of uterine polyps 
were considered feasible to remove in an outpatient 
setting, but failure to completely remove polyps was 
higher in conscious women owing to the limitations of 
miniature endoscopic equipment and patient tolera-
bility. Ongoing technological advances and refinement 
of treatment protocols may further improve feasibility. 
The clinical importance of differences in pain experi-
ence should be interpreted cautiously. Average pain 
scores during the outpatient procedure were of moder-
ate intensity but low postoperatively,19 and our quali-
tative research suggested that women believed that the 
discomfort of outpatient treatment was outweighed by 
convenience. Moreover, the differences may reflect the 
shorter interval between intervention and pain assess-
ment before leaving the outpatient clinic. The clinical 
importance of differences in acceptability should be 
interpreted in light of the high overall levels of patient 
acceptability and the convenience of outpatient treat-
ment. Practitioners may require additional training to 
become competent in therapeutic outpatient proce-
dures. However, proficiency should be quickly 
acquired given the familiarity of diagnostic outpatient 
hysteroscopy and the relative simplicity of uterine pol-
ypectomy.
strengths and limitations of this study
The strengths of this trial include strict randomisation, 
size, the multicentre design, low rates of losses to 
 follow-up, and use of outcome measures appropriate to 
the primary outcome. Some limitations of the study 
should be noted. These include variation in the practice 
of polypectomy, with several techniques and forms of 
instrumentation being utilised. Although we allowed 
flexibility for pragmatic reasons, there was greater vari-
ation in technique in the outpatient group. Not all 
women received the treatment to which they were orig-
inally allocated. However, per protocol analysis did not 
significantly alter the results, supporting the robust-
ness of the findings. The non-inferiority level of 25% 
might be considered large by some and hence a limita-
tion of the study; however, this was selected based on 
the perceived advantages of outpatient treatment. 
These advantages include avoiding a general anaes-
thetic, being treated immediately after diagnosis, tak-
ing only half a day’s leave from work, not having to 
arrange for childcare, and fewer hospital appointments. 
Ultimately, the results of this study showed that outpa-
tient polypectomy was at worst only 18% less effective 
than inpatient treatment.
Comparison with other studies
To our knowledge, this is the first large prospective, 
randomised controlled trial of outpatient compared 
with inpatient polypectomy for abnormal uterine 
bleeding. However, two small controlled studies that 
evaluated the two treatment settings have been pub-
lished.12 20 The first, an observational study from 2002, 
evaluated symptomatic improvement after polypec-
tomy in the outpatient compared with inpatient setting 
and found no difference in success of treating bleeding 
symptoms between the two groups; however, only 26 
patients were evaluated in the study.12 In the second 
study, a randomised controlled trial, outpatient polyp-
ectomy was as successful as the inpatient procedure, 
with good patient tolerability and low pain scores as 
well as faster recovery.20 The study did not, however, 
evaluate the effect of polypectomy on alleviation of 
patients’ symptoms.
Previously published studies of polypectomy for 
treating abnormal uterine bleeding have reported suc-
cess rates of 60–100%,12 21–28 which are similar to the 
73% and 80% reported in this study. However, these 
were mainly small, cohort studies of patients undergo-
ing inpatient polypectomy with general anaesthesia.
Owing to the large study population and the rigorous 
methodology of this trial, the results presented in this 
paper provide accurate data, confirming that outpatient 
treatment is non-inferior to inpatient treatment.
Conclusions and policy implications
By evaluating all types of uterine bleeding the general-
isability of the findings in this study has been enhanced. 
Although the procedural approaches studied represent 
options available in the United Kingdom, outpatient 
polypectomy is not available in all healthcare systems. 
Despite this caveat, outpatient, ambulatory, or office 
based interventions are becoming increasingly com-
mon across all medical disciplines, driven by advances 
in technology and a desire to enhance recovery.29–31 The 
simplicity of outpatient based interventions may 
encourage these treatments to be moved from hospital 
based environments to community settings. Thus the 
Outpatient Polyp Treatment trial is timely, novel, and 
relevant to contemporary clinical practice. Further ran-
domised controlled trials will be needed to evaluate the 
merits of innovative outpatient interventions against 
conventional inpatient practices across all surgical spe-
cialties.
In summary, this study found that outpatient polyp-
ectomy was non-inferior to inpatient polypectomy in 
alleviating abnormal uterine bleeding. Therapeutic out-
patient hysteroscopic services should be established in 
light of this finding and the overall safety, feasibility, 
and acceptability of the procedure. The relative advan-
tages and disadvantages of available treatment settings 
should be discussed with women so that they can make 
an informed decision.
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